In addition, different variants of CDKN2B-AS1 are associated with prostate cancer, and CCAT2 expression is upregulated in prostate cancer patients and affects prostate cancer development by altering the epithelial-mesenchymal transition (Fehringer et al., 2016; Zheng et al., 2016). This evidence concerns the gene CDKN2B and prostate cancer.